Q-omics provides the consensus-scored ANTXRL profile across patient tissues and cancer cell-line models. ANTXRL expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ANTXRL is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, ANTXRL RNA expression shows 7,751 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, BRCA, and THYM as cancer lineages where ANTXRL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANTXRL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANTXRL survival associations across molecular data types. ANTXRL RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANTXRL RNA expression–survival associations across cancer types. High ANTXRL expression shows unfavorable associations in KICH, KIRP, PAAD and ACC, but favorable associations in BLCA and ESCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for ANTXRL RNA expression.
This table summarizes ANTXRL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ANTXRL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANTXRL shows lower tumor expression in BRCA, KICH, KIRP and THCA and higher tumor expression in UCEC and LUAD. The BRCA box plot shows higher ANTXRL RNA expression in normal versus tumor tissue (log2 FC = −0.707, t-test p < 0.001).
This table shows molecular features associated with ANTXRL in patient tissues and cancer cell lines. In patient samples, ANTXRL shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANTXRL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
